BK-5Br-NM-AMT

BK-5Br-NM-AMT
Clinical data
Other namesβk-5Br-NM-αMT; β-Keto-5-bromo-N-methyl-αMT; β-Keto-5-bromo-N-methyl-AMT; α,N-Dimethyl-5-bromo-β-ketotryptamine; β-Oxo-5-bromo-α-methyl-NMT
Drug classMonoamine releasing agent
Identifiers
IUPAC name
  • 1-(5-bromo-1H-indol-3-yl)-2-(methylamino)propan-1-one
PubChem CID
Chemical and physical data
FormulaC12H13BrN2O
Molar mass281.153 g·mol−1
3D model (JSmol)
SMILES
  • CC(C(=O)C1=CNC2=C1C=C(C=C2)Br)NC
InChI
  • InChI=1S/C12H13BrN2O/c1-7(14-2)12(16)10-6-15-11-4-3-8(13)5-9(10)11/h3-7,14-15H,1-2H3
  • Key:WOUHPASMWLAZGG-UHFFFAOYSA-N

BK-5Br-NM-AMT, or βk-5Br-NM-αMT, also known as β-keto-5-bromo-N-methyl-αMT or α,N-dimethyl-5-bromo-β-ketotryptamine, is a monoamine releasing agent of the tryptamine, α-alkyltryptamine, and β-ketotryptamine families.[1]

It is known to induce the release of serotonin and dopamine, with respective EC50Tooltip half-maximal effective concentration values of 295 nM and 2,100 nM in rat brain synaptosomes, whereas norepinephrine release was not reported.[1] In contrast to many other tryptamines, the drug is inactive as an agonist of serotonin receptors including the 5-HT1, 5-HT2, and 5-HT3 receptors.[1] In addition, unlike other α-alkyltryptamines like α-methyltryptamine (αMT), it is inactive as a monoamine oxidase inhibitor (MAOI).[1]

BK-5Br-NM-AMT was first described in the literature by 2023.[1] It was patented by Matthew Baggott and Tactogen as a potential novel entactogen.[1] BK-5Br-NM-AMT is the 5-bromo derivative of BK-NM-AMT.[1][2][3][4] Other analogues of the drug include BK-5F-NM-AMT and BK-5Cl-NM-AMT.[1]

See also

References

  1. 1 2 3 4 5 6 7 8 WO 2022061242, Matthew Baggott, "Advantageous tryptamine compositions for mental disorders or enhancement", published 2023 March 24, assigned to Tactogen
  2. ↑ Yadav BJ (16 July 2019). Understanding Structure–Activity Relationship of Synthetic Cathinones (Bath Salts) Utilizing Methylphenidate. Theses and Dissertations (Doctor of Philosophy thesis). Virginia Commonwealth University. p. 40. doi:10.25772/MJQW-8C64. Retrieved 24 November 2024 – via VCU Scholars Compass.
  3. ↑ Blough BE, Decker AM, Landavazo A, Namjoshi OA, Partilla JS, Baumann MH, et al. (March 2019). "The dopamine, serotonin and norepinephrine releasing activities of a series of methcathinone analogs in male rat brain synaptosomes". Psychopharmacology (Berl). 236 (3): 915–924. doi:10.1007/s00213-018-5063-9. PMC 6475490. PMID 30341459.
  4. ↑ US 20240335414, Baggott MJ , Dalziel S, "Specialized combinations for mental disorders or mental enhancement", published 10 October 2024, assigned to Tactogen Inc.
This article is issued from WikiProjectMed. The text is available under Creative Commons Attribution-ShareAlike License unless otherwise noted. Additional terms may apply for the media files.